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Abstract Age-related macular degeneration (AMD) is
the leading cause of blindness among white caucasians
over the age of 50 years with a prevalence rate expected to
increase markedly with an anticipated increase in the life
span of the world population. To further expand our
knowledge of the genetic architecture of the disease, we
pursued a candidate gene approach assessing 25 genes and
a total of 109 variants. Of these, synonymous single nu-
cleotide polymorphism (SNP) rs17810398 located in death-
associated protein-like 1 (DAPL1) was found to be asso-
ciated with AMD in a joint analysis of 3,229 cases and
2,835 controls from five studies [combined PADJ = 1.15 9
10-6, OR 1.332 (1.187–1.496)]. This association was
characterized by a highly significant sex difference
(Pdiff = 0.0032) in that it was clearly confined to females
with genome-wide significance [PADJ = 2.62 9 10
-8, OR
1.541 (1.324–1.796); males: PADJ = 0.382, OR 1.084
(0.905–1.298)]. By targeted resequencing of risk and non-
risk associated haplotypes in the DAPL1 locus, we identi-
fied additional potentially functional risk variants, namely
a common 897-bp deletion and a SNP predicted to affect aElectronic supplementary material The online version of this
article (doi:10.1007/s12017-015-8342-1) contains supplementary
material, which is available to authorized users.
F. Grassmann  U. Friedrich  A. Milenkovic 
H. L. Schulz  B. H. F. Weber (&)
Institute of Human Genetics, University of Regensburg, Franz-
Josef-Strauss-Allee 11, 93053 Regensburg, Germany
e-mail: bweb@klinik.uni-regensburg.de
S. Fauser  T. Schick
Department of Ophthalmology, University Hospital of Cologne,
53127 Cologne, Germany
C. N. von Strachwitz
EyeCentre Southwest, 70563 Stuttgart, Germany
T. Bettecken
Max Planck Institute of Psychiatry, 80804 Munich, Germany
P. Lichtner  T. Meitinger
Institute of Human Genetics, Helmholtz Zentrum Munich,
85764 Neuherberg, Germany
T. Meitinger
Institute of Human Genetics, Technical University Munich,
81675 Munich, Germany
N. Arend  A. Wolf  C. Haritoglou  G. Rudolph
University Eye Hospital, Ludwig-Maximilians-University,
80336 Munich, Germany
U. Chakravarthy  G. Silvestri
Centre for Experimental Medicine, Queen’s University of
Belfast, Belfast BT12 6BA, Northern Ireland, UK
G. J. McKay
Centre for Public Health, Queen’s University of Belfast,
Belfast BT12 6BA, Northern Ireland, UK
S. Freitag-Wolf  M. Krawczak
Institute of Medical Informatics and Statistics, Christian-
Albrechts University, 24105 Kiel, Germany
R. T. Smith  J. C. Merriam  J. E. Merriam  R. Allikmets
Department of Ophthalmology, Columbia University,
New York, NY 10032, USA
R. T. Smith
Department of Ophthalmology, New York University School of
Medicine, New York, NY 10016, USA
123
Neuromol Med
DOI 10.1007/s12017-015-8342-1
putative binding site of an exonic splicing enhancer. We
show that the risk haplotype correlates with a reduced
retinal transcript level of two, less frequent, non-canonical
DAPL1 isoforms. DAPL1 plays a role in epithelial differ-
entiation and may be involved in apoptotic processes
thereby suggesting a possible novel pathway in AMD
pathogenesis.
Keywords Age-related macular degeneration 
Death-associated protein-like 1, DAPL1  Canonical
DAPL1 isoforms  Genetic association study
Introduction
Age-related macular degeneration (AMD) is a common
condition of complex etiology with major risk factors in-
cluding age, gender, smoking, ethnicity and genetics
(Zarbin et al. 2014). While AMD ultimately represents the
primary cause of blindness in developed countries (Res-
nikoff et al. 2004), its early form is less severe and char-
acterized by the mere presence of drusen and pigmentary
abnormalities in the macular area of the retina (Sarks et al.
1999). Late stage AMD manifests as choroidal neovascu-
larization and/or geographic atrophy and is associated with
irreversible central visual loss (Ferris et al. 2005; Zarbin
et al. 2014).
Genetic predisposition plays an important role in AMD
and is estimated to contribute up to 70 % of the disease risk
(Seddon et al. 2005). To date, two major and several minor
to moderate AMD susceptibility loci have been identified
with per allele odds ratios (OR) ranging from 1.3 to 3.4
(Fritsche et al. 2013). Of note, many of these loci suggest
an involvement of inflammatory processes and impaired
complement activation in AMD pathogenesis (Klein et al.
2005; Gold et al. 2006; Yates et al. 2007; Hughes et al.
2007; Fagerness et al. 2009), a fact that has raised major
interest in novel therapeutic approaches to address pro-
gression of the disease (Troutbeck et al. 2012).
Genetic variants associated with complex diseases are
usually identified by high-throughput genome-wide asso-
ciation studies of large numbers of cases and controls (Fu
et al. 2013). However, candidate gene studies with similar
sample sizes normally have greater statistical power to
detect genetic disease associations (Amos et al. 2011),
especially for genes not covered efficiently by
commercially available genotyping platforms (Wilkening
et al. 2009).
In this study, we aimed to expand our current knowledge
of the genetic architecture of AMD pathogenesis, following
a candidate gene approach. In a well-powered case–control
study, we screened 109 haplotype tagging variants in 25
genes for an association with late stage AMD. Attempts to
replicate any positive findings in over 4,000 individuals
from four previous studies revealed that variation in the
death-associated protein-like 1 (DAPL1) gene is sig-
nificantly associated with AMD. Importantly, this asso-
ciation is restricted to females and the variants of interest
correlate with altered transcription levels of specific retinal
isoforms of the DAPL1 gene.
Results
Association of 109 SNPs in 25 Candidate Genes
with Late Stage AMD
We first selected 25 genes and 109 haplotype tagging
single-nucleotide polymorphisms (SNPs) for an initial
analysis of 710 late stage AMD cases and 612 controls
(GER1) (Table 1; Supplementary Tables S1, S2). Criteria
for candidate gene selection included one or a combination
of the following: (1) causative involvement of the gene in
phenotypically related retinopathies, (2) known gene
function compatible with suspected AMD pathogenesis, (3)
specific or predominant gene expression in cellular sites of
primary AMD pathology, i.e., the photoreceptor/retinal
pigment epithelium (RPE)/choroid complex. All SNPs
were tested for significant deviation from Hardy–Weinberg
equilibrium (P \ 0.05) in all controls and in female and
male controls separately. This identified three SNPs
(RGR:rs2279227, rs4620343 and TRPM3:rs3812532)
which were subsequently excluded from further analyses.
Association tests adjusted for age and sex revealed a
nominally significant association using logistic regression
between AMD and three SNPs (DAPL1: rs17810398:C[T,
P = 0.016; RP1: rs9643828:T[C, P = 0.037; CST3:
rs2424577:C[T, P = 0.028) (Supplementary Table S2).
Replication of Three Nominally Significant
AMD-Associated Candidate Gene Variants
The three SNPs with a nominally significant AMD asso-
ciation were genotyped in an independent German repli-
cation sample consisting of 996 late stage AMD cases and
645 controls (GER2). The disease association could be
confirmed only for rs17810398 (P = 0.0014), a synony-
mous SNP in the coding sequence of the death-associated
protein-like 1 (DAPL1) gene (Table 2). Analysis of this
R. Allikmets
Department of Pathology and Cell Biology, Columbia
University, New York, NY 10032, USA
I. M. Heid
Department of Genetic Epidemiology, University of
Regensburg, 93053 Regensburg, Germany
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SNP in three other studies (681/367 late stage cases/con-
trols from US, 300/183 from UK and 542/1028 from
Cologne, Table 1) yielded consistent results (Table 2).
Combined analyses of the 3,229 cases and 2,835 controls
yielded a P value of 1.15 9 10-6 after adjustment for age,
sex and study (Table 2). Given that 106 tests were per-
formed, this result is significant at a significance level of
1.2 9 10-4 after Bonferroni correction. The risk allele
frequencies were similar in all four studies (13.3–14.3 % in
cases; 10.3–12.4 % in controls) and the per allele OR were
consistent in direction and magnitude (1.177 B OR B
1.530) with no indication for heterogeneity (I2 = 0).
Imputation and Replication of Genetic Variants
at the DAPL1 Locus
We next imputed the genotypes of 20,422 additional SNPs
around rs17810398 in the GER1 study based on 8 tagging
SNPs at the DAPL1 locus. After quality control, 517 SNPs
were included in the analysis and association signals
(PADJ \ 0.05) were obtained that were confined to a 154-kb
region devoid of any gene other than DAPL1 (Fig. 1; Sup-
plementary Table S3). Forty-eight imputed SNPs revealed
an association more significant than rs17810398 (PADJ =
0.027), with a minimum PADJ of 0.014 at rs74923781 and its
perfect proxy rs17810816:A[G (r2 = 1 based on 1,000
Genomes CEU samples) in DAPL1 intron 4. De novo
genotyping of rs17810816 gave consistent association in
terms of its direction in all four replication studies with a
nominal significance (PADJ B 0.05) attained in GER2 and
US. There was no indication of heterogeneity (I2 = 0). The
combined analysis yielded a PADJ of 1.76 9 10
-7 after ad-
justment for age, sex and study (Table 2; Fig. 1).Linkage
disequilibrium (LD) and haplotype analysis in the GER1
study revealed rs17810398 and rs17810816 to be in mod-
erate LD in controls (r2 = 0.55, Supplementary Figure S1).
Variants rs1710398 and rs17810816 Show a Female-
Specific Association
Stratifying the combined analysis by phenotype, including
AMD subtype and age-group, revealed no subgroup-
specific association for rs17810398 or rs17810816 (Fig. 2).
However, stratification by sex revealed that the association
signals of both SNPs were confined to females with gen-
ome-wide significance (rs1710398: PADJ = 2.62 9 10
-8,
rs17810816: PADJ = 2.68 9 10
-8). No AMD association
was evident in males (rs1710398: PADJ = 0.382,
rs17810816: PADJ = 0.141; Fig. 2, Supplementary Figure
S2; Table 2). The difference between sex-specific ORs was
statistically significant (rs17810398: Pdiff = 0.0034,
rs17810816: Pdiff = 0.014) at the 5 % level and was ob-
served in all studies analyzed (Supplementary Figure S2;
Table 2). In the combined study, the minor allele frequency
(MAF) of rs17810398 was lower in female controls than in
male controls and higher in female cases than in male
cases. A similar, albeit less pronounced effect was seen for
variant rs17810816.
DAPL1 Encodes Four Isoforms in Retina/RPE
For expression analysis of the DAPL1 locus, we scrutinized
expressed sequence tags (EST) and identified three entries
[GenBank accession numbers: DA417123 (thalamus),
BG818506 (oligodendroglioma), BI016096 (lung tumor)]
that suggested alternative splicing of DAPl1 gene products.
A potential correlation between rs1710398 and rs17810816
genotype and the occurrence of DAPL1 isoforms was in-
vestigated by 30-RACE experiments on four unrelated RPE/
retina tissue samples, two of which were homozygous
(ID_16 and ID_17) for the non-risk alleles and two of which
were heterozygous (ID_13 and ID_14) for the risk alleles.
After plasmid cloning of PCR products, we sequenced 1,200
cDNA clones and identified a total of 24 specific DAPL1
Table 1 Summary characteristics of participating study populations
Stage Study Number of individuals Study type Mean age (SD) [years] in
Cases GAa NVb GA&NVc Controls Total Cases Controls Fraction male (%)
1 GER1 710 161 423 126 612 1,322 Case/control 78.81 (6.64) 78.21 (5.28) 36.99
2 GER2 996 216 535 245 645 1,641 Case/control 76.15 (7.32) 73.05 (8.34) 37.72
2 US 681 165 516 0 367 1,048 Case/control 79.08 (8.48) 74.57 (7.10) 39.79
2 UK 300 38 252 10 183 483 Case/control 78.45 (9.75) 74.53 (8.91) 34.78
2 COL 542 55 459 28 1,028 1,570 Population based 75.49 (7.11) 69.51 (5.82) 42.93
1 ? 2 ALL 3,229 635 2,185 409 2,835 6,064 Mixed 77.68 (7.78) 73.14 (7.49) 39.36
a Geographic Atrophy
b Neovascular AMD
c Individuals with both GA and NV in either the same eye or in different eyes
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isoforms four of which (referred to as isoforms 1–4, Supple-
mentary Figure S3) were consistently found in all samples.
The most abundant isoform 1 (65–77 % over all samples)
corresponded to the DAPL1 reference sequence
(NM_001017920). Isoform 2 (6–12 %) and 3 (3–6 %) had not
been reported before, whereas isoform 4 (3–6 %) matched
EST BG818506 (Fig. 3a, b). Sequences corresponding to
DA417123 and BI016096 were not detected in the RPE/retina
RNA samples. RT-PCR analysis confirmed the expression of
isoforms 1–4 in human tissues with isoform 4 likely being
specific for RPE/retina (Supplementary Figure S4).
Resequencing of Candidate Regions at the DAPL1
Locus
In a search for additional risk variants at the extended
DAPL1 locus, we resequenced over 10 kb of intronic/
exonic sequences in each of 12 probands homozygous for
AMD risk alleles rs17810398:T and rs17810816:G and
eight probands homozygous for AMD non-risk alleles
rs17810398:C and rs17810816:A (Supplementary Figure
S3; Supplementary Table S4). Due to its extensive
saturation with repeat structures, resequencing of the ge-
nomic region around DAPL1 exon 4 of HQ179937 (iso-
form 4) was carried out for three individuals following sub-
cloning of PCR fragments. In total, we detected 33 se-
quence variants (Supplementary Table S5), three of which
(rs75277023:G[A, rs6146986, and rs144087548:A[T)
were in strong LD with rs17810398 and rs17810816 (r2 in
controls [ 0.9, Supplementary Figure S1). Variants
rs6146986 and rs144087548 were of particular interest as
the minor allele of the former represents a common 878-bp
deletion in DAPL1 intron 2, and the latter was predicted to
affect a putative binding site of an exonic splicing enhancer
(serine/arginine-rich splicing factor 1, SRSF1), 24-bp up-
stream of the most 30 exon shared by isoforms 3 and 4
(Supplementary Figure S3). Genotyping of rs6146986 and
rs144087548 in the GER1 study confirmed their strong LD
with rs17810398 (rs6146986: r2 = 0.93) and rs17810816
(rs144087548: r2 = 0.77) (Supplementary Figure S1;
Table 3). Additional cDNA resequencing of eight RPE/
retina tissues heterozygous for rs17810398 did not reveal
additional coding variants (Supplementary Table S6).
AMD-Associated Variants are Correlated
with Differential Expression of DAPL1 Isoforms
Samples heterozygous for rs17810398 (ID_13 and ID_14)
were characterized by a significantly different abundance
of non-risk and risk isoforms 3 and 4 (P \ 10-4). This was
not the case for isoforms 1 and 2 (Fig. 3c; Supplementary
Table S7). DAPL1 isoform expression in RPE/retina was
further evaluated in vivo by semi-quantitative cDNA se-
quencing (Fig. 4). Of 39 unrelated RPE/retina tissues
available, seven were heterozygous for AMD-associated
Fig. 1 Association with AMD of imputed and typed variants at the
DAPL1 locus. Association signals of markers are shown by the log-
P value from a logistic regression model (additive model adjusted for
age and sex; y-axis) and are plotted against their physical position (x-
axis). Stage 1 results (GER1 sample) are marked by filled (genotyped)
and open triangles (imputed). Association signals of rs17810398 and
rs17810816 in the pooled samples (3,229 cases and 2,835 controls)
are indicated by blue and green diamonds, respectively
Fig. 2 Subgroup analysis in the
combined study of candidate
SNPs rs17810398 and
rs17810816 in the DAPL1 gene.
OR and corresponding 95 %
confidence intervals are given
with the size of each rectangles
representing the respective
number of cases. AMD
phenotypic subgroups comprise
patients with geographic
atrophy (GA), and neovascular
AMD (NV) and both late stage
forms (GA&NV)
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variants rs17810398, rs6146986, rs17810816, and
rs144087548. In agreement with our 30-RACE data, these
samples revealed differential expression of isoforms 3 and
4 but not isoforms 1 and 2 (Fig. 4). Interestingly, sample
ID_11 was heterozygous for rs17810398, but homozygous
for the non-risk alleles of rs6146986, rs17810816, and
rs144087548. In this sample, expression intensities of
isoform 3 and 4 alleles were equal excluding rs17810398
as a functional variant involved in the differential expres-
sion of isoforms 3 and 4. This leaves rs6146986,
rs17810816, and rs144087548 or an as yet unknown but
correlated variant as the truly functional risk variant at the
DAPL1 locus.
Discussion
Here, we provide evidence that DAPL1 is an AMD-asso-
ciated gene and that its disease association is female-spe-
cific. To our knowledge, this is a first study reporting a sex-
specific genetic association with AMD at a genome-wide
significance level. Although lead SNPs rs17810398 and
rs17810816 have been imputed into large GWAS data sets,
neither variant has been identified before as AMD-associ-
ated (Fritsche et al. 2013). This is likely due to the female
specificity of the association as male/female ratios in multi-
center GWAS tend to differ greatly between cohorts
thereby potentially leading to reduced power. Behrens et al.
Fig. 3 Functional
consequences for isoform
expression of DAPL1 variants.
a Exon/intron structure of four
frequent DAPL1 isoforms (gene
orientation is from left to right).
SNP positions are marked by
vertical dotted lines.
b Frequency of the four
isoforms as determined from
sequencing 1,200 cDNA clones
that were obtained after 30-
RACE of four unrelated RPE/
retina tissue samples either
homozygous (ID_16, ID_17) or
heterozygous (ID_13, ID_14)
for the non-risk alleles of
rs17810398 and rs17810816.
c Distribution of rs17810398
alleles in heterozygous RPE/
retina tissue samples ID_13 and
ID_14. Statistically significant
deviations from the reference
transcript (i.e., isoform 1) are
indicated by asterisks
(P \ 0.0001)
Table 3 Association results in the GER1 study for four functional candidate SNPs in DAPL1
SNP Position on chr
2 (bp/hg19)
Major
allele
Minor allele MAFb Odds ratio (95 % CI) Pa R2c
Cases (%) Controls (%)
rs17810398 159,660,870 C T 13.3 10.5 1.314 (1.033–1.680) 0.027 Ref.
rs6146986 159,661,997–159,662,874 – 878-bp deletion 13.5 10.7 1.310 (1.033–1.667) 0.027 NA
rs17810816 159,671,992 A G 18.4 13.4 1.435 (1.163–1.778) 8.49 9 10-4 0.866
rs144087548 159,718,894 A T 17.4 13.8 1.296 (1.047–1.609) 0.018 0.735
a P from logistic regression adjusted for age and sex
b MAF: minor allele frequency calculated in 710 cases or 612 controls
c R2 to top variant based on CEU samples from the 1,000 genomes project
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(2011) have methodologically shown that gender-stratified
analyses greatly increase power to detect gender-specific
effects. Additionally, we have also observed the female-
specific association in our population-based sample (COL
study) after adjusting the analysis for age. This further
indicates that different study types increase the hetero-
geneity and therefore may lead to decreased power to de-
tect this association.
We also considered the possibility that age is a con-
founding factor in our study since (1) females are slightly
older than males and (2) cases are older than controls. If
any of the variants would be correlated with longevity, this
could potentially confound our analysis. However, we
found no evidence for a correlation between either SNP or
age, neither in cases, controls, females nor males separately
or analyzed jointly (P [ 0.05). Additionally, we note that
logistic regression analyses were adjusted for age in our
analyses. Furthermore, two SNPs at the DAPL1 locus
(rs9869 and rs10497199) were investigated in a recent
study by Flachsbart et al. 2010. For these two variants, the
authors found no association with longevity (P [ 0.5).
Variant rs9869 is weakly linked to markers rs17810398
(r2 = 0.13) and rs17810816 (r2 = 0.1), while rs10497199
is independent of either variant (r2 \ 0.1). Taken together,
these findings have led us to exclude a confounding effect
of age in our analysis.
The observed association in the present study could
eventually be explained by a population substructure in our
cases or controls from the UK or US. Although we cannot
definitely exclude such a possibility, it is of note that
frequency and effect sizes of the two DAPL1 risk variants
rs17810398 and rs17810816 (in males, females and jointly)
observed in the UK and US study are similar to the fre-
quencies observed in the combined German cohort
(Table 2). The German samples derive from a genetically
homogenous population from a small area in southern
Germany. Homogeneity was estimated previously from
genome-wide data available for a subset of cases (Fritsche
et al. 2013). From these data, we conclude that the US and
UK study primarily consists of Caucasians which are ge-
netically similar to the German cohort and, if at all,
population substructure may only exert a minor effect on
study outcome.
Although DAPL1 is evolutionarily conserved, only little
is known about its function. It has been shown to be
abundantly expressed in the retina/RPE transcriptome
(Schulz et al. 2004) as well as in epidermis, esophageal
epithelium, and tongue epithelium where it appears to be
involved in the early stages of stratified epithelial differ-
entiation (Sun et al. 2006). Based upon strong amino acid
sequence similarities, DAPL1 has also been connected to
the death-associated protein (DAP), a basic, proline-rich
protein of 15-kD molecular weight that acts as a positive
mediator of programmed cell death upon induction by in-
terferon-gamma (Deiss et al. 1995). Clarification of the
cellular function of DAPL1 in the RPE/retina is required to
allow more detailed insight into this novel pathway of
AMD pathogenesis.
We have shown that DAPL1 is present in a multitude of
correctly spliced isoforms, two of which, isoforms 3 and 4,
Fig. 4 Semi-quantitative cDNA sequencing of eight RPE/retina
tissue samples heterozygous for synonymous coding SNP
rs17810398:C[T. The chromatograms of the variant nucleotide at
rs17810398 flanked by ±3 bp are shown for isoforms 1 & 2, 3, and 4.
Isoforms were specifically amplified by three different exon-spanning
primer combinations. Genotypes of the four candidate variants are
given above the chromatograms. The sample heterozygous for
rs17810398 but homozygous for the non-risk alleles of rs6416986,
rs17810816, and rs144087548 is highlighted in red
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were specifically down-regulated in the presence of AMD-
associated alleles. Although we could not identify the
causative variant at the DAPL1 locus, we excluded lead
SNP rs17810398 as the presence of the T-risk allele in one
patient (ID_11) had no influence on the transcript levels of
isoform 3 or 4. Notably, the unique C-terminus of isoform
4 encodes two potential transmembrane domains with
significant homology to the rhodopsin-like G protein-cou-
pled receptor (GPCR) family. Another member of the
GPCR family, the G protein-coupled estrogen receptor 1
(GPER) plays a role in intracellular signaling following
estrogen binding and could provide a useful lead when
searching for factors involved in sex-dependent AMD risk.
While at present we cannot explain the gender-specificity
of the association with DAPL1, our results provide a
starting point at a molecular level to investigate why AMD
is more frequent in women than in men (Owen et al. 2012).
Taken together, we investigated 25 gene loci of interest
to AMD pathology and excluded all but one from being
disease-associated. Our data implicate DAPL1 as a novel
gene involved in AMD pathology although the cellular
functions of this gene and of its various differentially
spliced transcripts remain elusive. Our study revealed a
correlation between risk variants at rs17810398 and
rs17810816 on the one hand and expression levels of
DAPL1 isoforms 3 and 4 on the other, the latter being
specifically expressed in RPE/retina tissue. We also re-
ported a significant sex difference of the effect of DAPL1
where only females showed an association signal at this
locus. Although speculative at present, this sex difference
may be explained by a role of DAPL1 variants in sex-
specific signaling processes. Our findings add another piece
to the puzzle of the genetic architecture of AMD, which,
once completed, should allow refined identification of in-
dividuals at risk for this disease.
Methods
Subjects
Five independent studies were included in our study
comprising a total of 3,053 unrelated Caucasian patients
with clinically documented late stage AMD (cases) and
2,738 unrelated age and individuals with comparable age
range and ethnicity without signs of macular disease (-
controls) (Table 1). All data were available for analysis at
the analysis center in Regensburg. Discovery study GER1
(stage 1) included 710 AMD patients and 612 controls
from the University Eye Clinic of Wu¨rzburg (Germany).
The four replication studies (Stage 2) comprised (1) 996
AMD patients and 645 controls from the University Eye
Clinics in Mu¨nchen, Tu¨bingen and Wu¨rzburg (Germany)
(GER2); (2) 681 AMD patients and 367 controls from
Columbia University (New York, USA) (US); (3) 300
AMD patients and 183 controls from the Royal Victoria
Hospital (Belfast, UK) (UK); and (4) 542 AMD patients
and 1,028 controls from the Department of Ophthalmology
at the University Hospital Cologne, Germany (COL). Cases
and controls were examined by trained ophthalmologists.
Stereo fundus photographs were graded according to
standardized classification systems as described previously
(Grassmann et al. 2012). The study was conducted at all
sites in strict adherence to the tenets of the Declaration of
Helsinki and was approved by the respective Ethics
Committees at the University Eye Clinics of Wu¨rzburg,
Mu¨nchen and Tu¨bingen, by the Institutional Review Board
at Columbia University, by the Research Ethics Committee
of Queen’s University Belfast and by the local Ethics
Committee in Cologne.
Genotyping
Genomic DNA was extracted from peripheral blood
leukocytes according to established protocols. Genotyping
of SNPs was carried out by direct sequencing, TaqMan
SNP genotyping (Applied Biosystems, Foster City, USA)
or by primer extension of multiplex PCR products and
subsequent allele detection by matrix-assisted laser des-
orption/ionization time of flight (MALDI-TOF; Sequenom,
San Diego, USA). Direct sequencing was performed with
the Big Dye Terminator Cycle sequencing kit version 1.1
(Applied Biosystems, Foster City, U.S.A.) according to the
manufacturer’s instructions. Reactions were analyzed with
an ABI Prism 3130xl sequencer (Applied Biosystems).
TaqMan pre-designed SNP genotyping assays (Applied
Biosystems) were used according to the manufacturer’s
instructions. The rs144087548 variant was genotyped by
polymerase chain reaction (forward primer: 50-CGC AGA
CAT GAT GCT GGG GGT-30; reverse primer: 50-ACA
TGC AAG ACG GGG AAT TGA-30) followed by Hpy-
CH4III digestion (New England Biolabs, Ipswich, USA)
and restriction fragment length analysis. All SNPs showed
high genotyping quality with an average call rate[98 % in
each of the five case–control samples.
Statistical Methods
Discovery Study
We excluded three SNPs [rs2279227 (RGR), rs4620343
and rs3812532 (TRPM3)], each with significant deviation
from Hardy–Weinberg equilibrium (HWE, P B 0.05) in
the control group of the discovery sample. SNP association
analysis was carried out by logistic regression adjusted for
age and sex. All analyses modeled an additive genetic
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effect and the genotype was coded as the number of alleles
present at a given variant (i.e., 0, 1 or 2).
Replication Studies and Combined Analysis
All SNPs were in HWE (P [ 0.05). We used the same tests
for SNP association analysis as in the discovery study. We
also combined the individual data from all five studies and
also adjusted the respective analyses by study center (coded
as factors). The I2 measure was computed to measure be-
tween-study heterogeneity. We also conducted sex-stratified
analyses for each study separately and for all study samples
combined. Sex differences were asses for statistical sig-
nificance using a t test derived from sex-specific beta esti-
mates and corresponding standard errors.
All reported P values were two-sided except where
noted otherwise. All SNP association analyses were carried
out with R (v3.0.1, http://R-Forge.R-project.org/). To allow
a more detailed inspection of the genomic region of in-
terest, measures of LD were calculated using R package
snp.plotter (Luna and Nicodemus 2007).
Imputation of SNPs
Prior to imputation, 8 tag SNPs in DAPL1 were phased in the
GER1 study individuals using SHAPEIT2 (Delaneau et al.
2013). Then, untyped SNPs were imputed with IMPUTE2
(Howie et al. 2009) using the 1,000 Genomes Phase I inte-
grated haplotypes (release 20110521) as reference panel.
After the exclusion of SNPs with imputation quality (‘‘info’’)
\0.5, the genotype probabilities (dosages) of the remaining
SNPs were also analyzed by logistic regression in R, using an
additive model adjusted for age and sex.
Genomic Resequencing
Genomic resequencing was done for regions of interest
defined by the presence of certain gene elements (putative
promoter, coding exons of transcripts NM_001017920.2,
HQ179935, HQ179936, and HQ179937) or conserved
elements based upon the ‘‘46-Way Most Cons’’ track of the
UCSC genome browser, NCBI Build 37/hg19. Regions
within extensive repeat structures were excluded (Supple-
mentary Figure S3). Resequencing primers are listed in
Supplementary Table S4.
Prediction of Functional Impact of Risk Variants
The functional impact AMD-associated SNPs (with known
dbSNP ID) on RNA processing as well as protein se-
quence, structure and function was predicted using the
web-based ‘‘SNP Function Prediction’’ tool implemented
in the ‘‘SNPinfo Web Server’’ (http://snpinfo.niehs.nih.
gov/index.html) (Xu and Taylor 2009). For newly identi-
fied SNPs, we used ESEfinder 3.0 to predict the effect of a
given SNP allele on putative exonic splicing enhancers
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi)
(Cartegni et al. 2003).
Characterization of Major Splice Variants of DAPL1
in Human Retina/RPE
To determine major splice variants and functional
polyadenylation sites, 30 rapid amplification of cDNA ends
(30-RACE) experiments were conducted. RNAs from RPE/
retina tissues that were either heterozygous (ID_13 and
ID_14) or homozygous (ID_16 and ID_17) for the non-risk
rs17810398:C allele were isolated by RNeasy Mini Kit fol-
lowed by DNAse I treatment (QIAGEN, Hilden, Germany).
30-RACE was conducted with the FirstChoice RLM-RACE
Kit (Applied Biosystems/Ambion, Austin, USA) according
to the manufacturer’s instructions. Forward primers for first
and second (nested) PCR were 50-GCA CTG GCA CACG
CTA TG-30 and 50-TTG GCA CCT TGG AAA GAC ATA
CC-30, respectively. Amplified RACE products were ligated
into the pGEM-T vector (Promega, Madison, USA). PCR
products were obtained with M13 forward and M13 reverse
primers from a total of 1,200 clones. Of these, 597 clones
were sequenced; the remaining 603 could unequivocally be
assigned to DAPL1 isoform 1 (NM_001017920.2,
HQ179934) by visual gel inspection. The sequences of iso-
forms 2–6 were submitted to GenBank (HQ179935,
HQ179936, HQ179937, HQ179938, HQ179939).
Expression Analysis and Semi-quantitative
Resequencing
Eight RPE/retina tissues with risk variant genotypes as
given in Fig. 3 and Supplementary Table S6 were used as
templates to amplify isoform-specific PCR products with
forward primer 50-GCA CTG GCA CAC GCT ATG-30 and
the isoform-specific reverse primers 50-CGA GGC TGC
TGA ATA ATG TAG-30 (isoform 1 & 2), 50-TCT GGA
TCC TCT GAG CTT CTT CTC-30 (isoform 3) or 50-CTG
GAT CCT CTG AGC TTC TTG TGT-30 (isoform 4),
followed by sequencing with the forward primer. Primers
for the GUSB gene were 50-ACT ATC GCC ATC AAC
AAC ACA CTC ACC-30 and 50-GTG ACG GTG ATG
TCA TCG AT-30. For tissue samples, sex was determined
with fluorescence-based PCR analysis of the homologous,
X- and Y-linked genes AMELX and AMELY as described in
Sullivan et al. (1993).
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